

Erratum: AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137 [Med. Phys. 36, 5310-5322, 2009]

Ravinder Nath^{a)}

Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06510, USA

William S. Bice

International Medical Physics, San Antonio, TX 78259, USA

Wayne M. Butler

Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV 26003, USA

Zhe Chen

Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06510, USA

Ali S. Meigooni

Department of Radiation Medicine, North Shore University Hospital-Long Island Jewish Health System, Manhasset, NY 11030, USA

Vrinda Narayana

Department of Radiation Oncology, Providence Cancer Center, Southfield, MI 48075, USA

Mark J. Rivard

Department of Radiation Oncology, Tufts University School of Medicine, Boston, MA 02111, USA

Yan Yu

Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA

We would like to update the Table I in the aforementioned report¹ by the following:

TABLE I. Examples of radiobiological indices for uniform dose distributions. (Calculated with: $\alpha = 0.15 \text{ Gy}^{-1}$, $\beta = 0.05 \text{ Gy}^{-2}$, $\alpha/\beta = 3.0 \text{ Gy}$, $T_p = 42 \text{ days}$, repair half-life of 0.27 h, $N_0 = 1 \times 10^6$, and radioactive decay half-life of 59.4, 16.991, and 9.7 days for ^{125}I , ^{103}Pd , and ^{131}Cs , respectively).

| Indices | Radionuclide | | |
|------------------------|------------------|-------------------|-------------------|
| | ^{125}I | ^{103}Pd | ^{131}Cs |
| Dose (Gy) | 145.0 | 125.0 | 120.0 |
| BED (Gy) | 111.1 | 115.4 | 117.3 |
| TCP (%) | 94.4 | 97.0 | 97.7 |
| T_{eff} (day) | 234.2 | 94.0 | 61.0 |

This update corrects a variable referencing error in the Excel spreadsheet used in the numerical calculation of cumulative dose at effective treatment time which also affected the BED and TCP values listed in the table. In addition, the values of radioactive decay half-life used in numerical calculation are now included to facilitate easy comparison by readers in the future.

We thank Nelson Miksys, Mehan Haidari, and Rowan Thomson, Ph.D. for bringing to our attention their effort in reproducing the results of original Table I which led to this update.

^{a)} Author to whom correspondence should be addressed. Electronic mail: ravinder.nath@yale.edu

REFERENCE

1. Nath R, Bice WS, Butler WM, et al. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137. *Med Phys.* 2009;36:5310–5322.